Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Soon Alan will be but a mere bad dream we all wished we hadn't had.
Completely disagree with you Bridgedogg1.
"Building out a diagnostics division made perfect sense"? For a company that had no Dx experience and, as it turned out, no skill? Pull the other one. Dx has STILL not produced anything. "If", if, if. Name me one successful Dx business worth more than a successful Tx business.
Dx is NOT projected by Avacta to be "be cash generative in 6 months". To say so is a blatant falsehood.
"The problem is the therapeutics is draining all the cash." Firstly, Dx is draining the cash for no perceivable future benefit. Secondly, it's a given that that's what Tx does until profitable.
I used to think you were sensible. Now I think you're an idiot.
Were they a late runner...
'In light of the strong demand received both from existing investors and potential new holders, the Board has decided to increase the size of the Placing from approximately £20 million to £25.7 million.'
If they bought in full 3.3% during Placing then it was only £4.7m.
I’ve been critical for years, thank you. No issues with the M&A, it’s the original Dx that’s drained the cash - Alan’s pet project. It’s no shock that Tx needs cash on an ongoing basis, if we could have raised at a 10% discount, why didn’t we? I blame Alan, he had PI cash on the table and chose to grease city boys to get what he views as a prestige name on the register. Unless Bella’s theories are right, it’s looking like he was led by his ego. He was delighted by courting Sequoia Carpets, it meant nowt to the business. If they were strategic partners and willing to provide on going cheap finance, kudos to him. They weren’t, we’re just a punt for them. If it’s sold for £1bn, it’s a massive failure.
How long have you held avct and what loss are you sitting on?
How did Deep Verge go?
I don't mind admitting my losses but the way you carry on its as though your very careful, well researched stock picks have proved and paved the way to success....
I’d be fascinated by a discussion thread on the general board with all trades posted as they happen.
Otherwise, I imagine some dribbling window lickers with a set of crayons absolutely love the painting by numbers series from the catastrophically failed gambler.
I think all the critisism of AS is easy with hindsight. This was 17p pre covid. Building out a diagnostics division made perfect sense, if there was another pandemic it would be worth much more than the therapeutics. £50m spent on a business that will be cash generative in 6 months and £21m revenue is pretty savvy. The problem is the therapeutics is draining all the cash. The financial markets are now broken resulting in a undervalued share prices and a lack of any financing on reasonable terms. A few years ago we could have done the raise at a 10% discount, You cant really blame AS for this? The CFO completely dropped the ball on the financing and AS should have realised that he had to do some sort of deal to bring in some cash rather than go for the big prize in the changing environment. Ultimately when this is sold for £1bn because we kept hold f the IPS no one will be saying this is all thanks to AS not selling us out early but the truth is that is exactly why we will be worth so much.
Genuine question - Does anyone here (hands down if you are one of his aliases) actually value Ronnie Wynbores 'contributions' here?
Just opportunists based on the buy in price...
And they're not a European Specialty Healthcare Fund..
So where's the TR1...they've past 3%...
Thank you wynnie
Lombard Odier Investment Managers
https://www.lombardodier.com/home.html
Perhaps Conifer Management & Baillie Gifford dropped below 3% : O/S shares have increased from 283,614,110 to current 360,042,104 ?
--------------------
As at 24th October 2023
"Significant Shareholdings
Current significant shareholders are as follows:
Conifer Management, LLC 4.4%
Baillie Gifford & Co Limited 3.7%
As at 24th October 2023 the company has 283,614,110 ordinary shares of 10p each in issue."
Large lates incoming...200k and 300k
@PJT12......spot on...I accept the need not to dwell on the past but the whole acquisition stuff was ego driven and part of AS's personal dream rather than what was best for Avacta PLC.
Nonsense.
Avacta’s most explosive self-appointed IR agent is still bashing away on X/Twitter. Says AVCT “should be” valued at 490p, and predicts a $5bn-$8bn bid during the next 12m…
"Significant Shareholdings
Current significant shareholders are as follows:
Lombard Odier Investment Managers 3.3%
As at 30th April 2024 the company has 360,042,104 ordinary shares of 10p each in issue."
Slowing replacing AS comments with CC comments .
https://avacta.com/investors/ceo-welcome/ 0 2024-05-01 14:10 +00:00
https://avacta.com/investors/key-information/ 0 2024-05-01 14:17 +00:00
https://avacta.com/investors/corporate-governance/ 0 2024-05-01 14:38 +00:00
https://avacta.com/investors/results-presentations/ 0 2024-05-01 14:45 +00:00
https://avacta.com/investors/investor-resources/ 0 2024-05-01 14:47 +00:00
Klaus Hochleitner - we need to start all over again and bring him back into the Avacta fold.
Quality assessment Nano. Think you hit the nail on the head in your final sentence of point 3. Pretty sure Alan felt he knew best and enjoyed his lifestyle generating position. His stubbornness has held the company back. Perhaps there have been clashes and that's why CC was confirming that everything was now on the table. Good luck to her, here's hoping she has a good strategic head on her shoulders.
Where the Coris and Launch Diagnostics acquisitions were concerned, weren't they most likely just down to AS's previous stated aims of several years ago when developing the LFT: for Avacta to become a household name on the wider testing front (beyond Covid). I just think his ego (yet again) got ahead of him and he didn't realise his limited capabilities on the finance front.
We need a hold and close at 49p. that would be a third time through with also a third time supporting the 44p low.
That would give a firm trading range
a close above 54p would be bullish
Great post Nanomat